Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pradere

Showing results (401-410 of 412) with videos related to

Pageof 42
Sort By:
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
World Journal of Urology|January 11, 2026
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter studyPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
Urologic Oncology|July 19, 2022
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancerWojciech Krajewski, Júlia Aumatell, José Daniel Subiela, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
World Journal of Urology|June 10, 2026
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomesValerio Santarelli, Vincenzo Asero, Roberta Corvino, et al.
Pageof 42

Showing results (401-410 of 412) with videos related to

Sort By:
Pageof 42
European Urology Oncology|February 14, 2024
Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk DynamicsJosé Daniel Subiela, Wojciech Krajewski, Daniel A González-Padilla, et al.
World Journal of Urology|January 11, 2026
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter studyPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
BJU International|March 3, 2026
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groupsAna Fernández-Mardomingo, Jose Daniel Subiela, Alberto Artiles Medina, et al.
European Urology Oncology|June 17, 2022
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder CancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
World Journal of Urology|October 28, 2025
Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year studyMario de Angelis, Francesco Pellegrino, Pietro Scilipoti, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 16, 2026
Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerPietro Scilipoti, Mario de Angelis, Constance Thibault, et al.
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
Urologic Oncology|July 19, 2022
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancerWojciech Krajewski, Júlia Aumatell, José Daniel Subiela, et al.
Nature Reviews. Urology|April 1, 2026
Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensusRoberto Contieri, Paolo Gontero, Rodolfo Hurle, et al.
World Journal of Urology|June 10, 2026
Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomesValerio Santarelli, Vincenzo Asero, Roberta Corvino, et al.
Pageof 42